{"nctId":"NCT02814643","briefTitle":"Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma","startDateStruct":{"date":"2016-07-01","type":"ACTUAL"},"conditions":["Asthma"],"count":103,"armGroups":[{"label":"Benralizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Benralizumab","Drug: Seasonal influenza virus vaccine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Benralizumab Placebo","Drug: Seasonal influenza virus vaccine"]}],"interventions":[{"name":"Benralizumab","otherNames":[]},{"name":"Benralizumab Placebo","otherNames":[]},{"name":"Seasonal influenza virus vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female and male patients aged 12 to 21 years, inclusive, at the time of Visit 1\n* Weight of ≥40 kg\n* Documented history of current treatment with Inhaled corticosteroids (ICS) and long-acting β2 agonists (LABA)\n* Morning pre-bronchodilator forced expiratory volume in 1 second (FEV1) of \\>50% predicted at Visit 1 or Visit 2.\n* Airway reversibility (FEV1 \\>12% and 200 ml) demonstrated at Visit 1 or Visit 2 using the Maximum Post-bronchodilator Procedure OR\n* Airway reversibility documented in the previous 12 months prior to Visit 1\n* An exacerbation, 1 or more, that required oral corticosteroids in the previous year OR\n* Any condition assessed by patient recall over the previous 2-4 weeks\n\nExclusion Criteria:\n\n* Clinically important pulmonary disease other than asthma\n* Known history of allergy or reaction to the Investigational Product formulation or influenza vaccine\n* Receipt of an influenza vaccine within 90 days prior to randomization\n* Poorly controlled asthma during the screening period that requires treatment with oral corticosteroids or a hospitalization/emergency room visit for the treatment of asthma\n* Acute illness or evidence of significant active infection or known influenza infection during the current flu season","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Postdose Strain-specific Hemagglutination-inhibition (HAI) Antibody Geometric Mean Fold Rise From Week 8 to Week 12","description":"To compare the geometric mean fold rises in influenza strain-specific hemagglutination-inhibition responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \\[log(z) x\\]), where \"x\" is the postdose HAI antibody titer fold rise from Week 8 and \"z\" is the natural logarithm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":"1.22"},{"groupId":"OG001","value":"3.13","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.25","spread":"1.18"},{"groupId":"OG001","value":"3.85","spread":"1.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"1.16"},{"groupId":"OG001","value":"3.17","spread":"1.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.08","spread":"1.19"},{"groupId":"OG001","value":"3.27","spread":"1.19"}]}]}]},{"type":"PRIMARY","title":"Postdose Strain-specific Hemagglutination-inhibition Antibody Geometric Mean Titers Obtained at Week 12","description":"To compare the geometric mean titers of hemagglutination-inhibition antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"521.06","spread":"1.13"},{"groupId":"OG001","value":"518.60","spread":"1.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"170.73","spread":"1.15"},{"groupId":"OG001","value":"219.35","spread":"1.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.47","spread":"1.13"},{"groupId":"OG001","value":"63.15","spread":"1.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.10","spread":"1.14"},{"groupId":"OG001","value":"66.85","spread":"1.14"}]}]}]},{"type":"PRIMARY","title":"Proportion of Patients Who Experienced a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a ≥4-fold Rise in Hemagglutination-inhibition Antibody Titer From Week 8 to Week 12","description":"To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥4-fold rises in hemagglutination-inhibition antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.440","spread":null},{"groupId":"OG001","value":"0.306","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.500","spread":null},{"groupId":"OG001","value":"0.490","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.480","spread":null},{"groupId":"OG001","value":"0.490","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.560","spread":null},{"groupId":"OG001","value":"0.408","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination-inhibition Antibody Titer ≥40 at Week 12","description":"To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥40-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"251.9"},{"groupId":"OG001","value":"1.00","spread":"191.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.980","spread":"136.2"},{"groupId":"OG001","value":"0.980","spread":"168.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.860","spread":"144.9"},{"groupId":"OG001","value":"0.796","spread":"115.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.780","spread":"178.7"},{"groupId":"OG001","value":"0.878","spread":"162.2"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination Inhibition Antibody Titre ≥320 at Week 12","description":"To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥320-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.840","spread":null},{"groupId":"OG001","value":"0.857","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.500","spread":null},{"groupId":"OG001","value":"0.612","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.020","spread":null},{"groupId":"OG001","value":"0.020","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.080","spread":null},{"groupId":"OG001","value":"0.041","spread":null}]}]}]},{"type":"SECONDARY","title":"Postdose Strain-specific Microneutralization Antibody Geometric Mean Fold Rise From Week 8 to Week 12","description":"To compare the geometric mean fold rises in influenza strain-specific microneutralization antibody responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \\[log(z) x\\]), where \"x\" is the postdose microneutralization antibody titer fold rise from Week 8 and \"z\" is the natural logarithm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"521.4"},{"groupId":"OG001","value":"4.4","spread":"329.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"149.8"},{"groupId":"OG001","value":"3.6","spread":"210.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"148.9"},{"groupId":"OG001","value":"3.2","spread":"141.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"224.1"},{"groupId":"OG001","value":"3.5","spread":"195.3"}]}]}]},{"type":"SECONDARY","title":"Postdose Strain-specific Serum Microneutralization Antibody Geometric Mean Titers Obtained at Week 12","description":"To compare the geometric mean titers of microneutralization antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3774.1","spread":"181.7"},{"groupId":"OG001","value":"3969.1","spread":"154.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4307.5","spread":"169.0"},{"groupId":"OG001","value":"4351.3","spread":"171.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"350.2","spread":"103.6"},{"groupId":"OG001","value":"336.2","spread":"114.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164.5","spread":"178.5"},{"groupId":"OG001","value":"234.4","spread":"135.0"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Who Experience a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a ≥4-fold Rise in Microneutralization Antibody Titer From Week 8 to Week 12","description":"To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥4-fold rises in microneutralization antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.420","spread":"251.9"},{"groupId":"OG001","value":"0.408","spread":"191.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.440","spread":"136.2"},{"groupId":"OG001","value":"0.429","spread":"168.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.280","spread":"144.9"},{"groupId":"OG001","value":"0.388","spread":"115.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.400","spread":"178.7"},{"groupId":"OG001","value":"0.388","spread":"162.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Asthma Control Questionnaire 6 (ACQ-6) Score at Week 12","description":"To compare the change from baseline at Week 12 in mean ACQ-6 score between patients receiving benralizumab 30mg and patients receiving placebo. The ACQ-6 assesses asthma symptoms (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and short-acting β2 agonist use). Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score is the mean of the responses to each question. Mean scores of ≤0.75 indicate well-controlled asthma, scores between 0.75 and ≤1.5 indicate partly controlled asthma, and a score \\>1.5 indicates not well controlled asthma","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":null},{"groupId":"OG001","value":"-0.42","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":51},"commonTop":["Nasopharyngitis","Headache","Asthma","Oropharyngeal pain","Gastroenteritis viral"]}}}